Inducing Oncoprotein Degradation to Improve Targeted Cancer Therapy()

Over the past decade, inhibition of the kinase activities of oncogenic proteins using small molecules and antibodies has been a mainstay of our anticancer drug development effort, resulting in several Food and Drug Administration–approved cancer therapies. The clinical effectiveness of kinase-target...

Descripción completa

Detalles Bibliográficos
Autores principales: Ray, Dipankar, Cuneo, Kyle C., Rehemtulla, Alnawaz, Lawrence, Theodore S., Nyati, Mukesh K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4611070/
https://www.ncbi.nlm.nih.gov/pubmed/26476077
http://dx.doi.org/10.1016/j.neo.2015.08.008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4611070/
https://www.ncbi.nlm.nih.gov/pubmed/26476077
http://dx.doi.org/10.1016/j.neo.2015.08.008

Ejemplares similares